Home >> Marketplace Archives >> Natera, Institut Jules Bordet collaborate

Natera, Institut Jules Bordet collaborate

Print Friendly, PDF & Email

August 2018—Natera announced a research collaboration with the Institut Jules Bordet, in Brussels, using the company’s Signatera research-use-only circulating tumor DNA assay to evaluate molecular response and minimal residual disease in women with early stage breast cancer.

Natera will analyze approximately 300 plasma specimens prospectively collected and banked from 80 patients diagnosed with nonmetastatic breast cancer who received neoadjuvant chemotherapy followed by surgery and who were then monitored for recurrence with serial imaging. The study will correlate results of the Signatera assay with clinical outcomes, including pathological response and event-free survival. The study is led by Michail Ignatiadis, MD, PhD, attending physician in the medical oncology department of Institut Jules Bordet and assistant professor, Université Libre de

Natera, 844-778-4700


Check Also

Natera to continue using Illumina’s HiSeq 2500, 10/13

Illumina and Natera announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq 2500 sequencing system and associated consumables for performing Natera’s noninvasive prenatal test (NIPT) Panorama.